Last mentioned: Mar 25, 2026
Keytruda Patent Cliff
Expected loss of exclusivity for Merck's top-selling cancer drug, Keytruda.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Data Review
Expected first quarterly report on screening uptake and identification rates in Scotland.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Part 2 Expansion
Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
Anticipated Milestone
Expected Phase 1 data readout for MRT-6160 in autoimmune diseases.
Terns Acquisition Announced
Merck agrees to buy Terns Pharmaceuticals for $6.7 billion to acquire TERN-701.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Q4 2025 Earnings
Reported year-end financial results and updated 2027 cash runway.
Primary Objectives Met
Telix announces Part 1 achieved all primary safety and dosimetry goals.
Scotland Launch
Scotland officially begins nationwide screening for all newborns.
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Novartis Settlement
Novartis announces a confidential settlement with the Henrietta Lacks estate.
Part 1 Completion
Enrollment for the safety and dosimetry portion of the study concludes.
Olpruva Scaling
Zevra reports steady growth in urea cycle disorder market share.
Novartis Expansion
Voyager expands its capsid discovery collaboration with Novartis.
MRT-2359 Update
Released preliminary Phase 1 safety and target engagement data.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC treatment.
Trial Initiation
ProstACT GLOBAL Phase 3 study begins enrollment.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs.
Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.
Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Novartis has reached a confidential settlement with the estate of Henrietta Lacks, ending litigation over the unauthorized use of her 'immortal' HeLa cells. This marks the latest in a series of legal victories for the Lacks family against pharmaceutical giants that profited from cells taken without consent in 1951.
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
This page surfaces every story mentioning Novartis across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Novartis was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |